Preemptive attack of Sanofi to launch Toujeo next month in novel basal insulin competition

Sanofi-Aventis has created a foundation to be a step ahead in the competition of a novel insulin against Novo Nordisk.

According to Sanofi, ‘Toujeo(generic name: insulin glargine),’ a next-generation once-daily long-acting basal insulin, will be launched with health insurance benefit from the 1^st of the next month.

Previously, Sanofi and Novo Nordisk have made psychological warfare to preoccu...